Neurogene Stock Operating Margin
| NGNE Stock | 22.73 0.09 0.40% |
Neurogene fundamentals help investors to digest information that contributes to Neurogene's financial success or failures. It also enables traders to predict the movement of Neurogene Stock. The fundamental analysis module provides a way to measure Neurogene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurogene stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (0.85) | (0.89) |
Neurogene | Operating Margin |
Neurogene Company Operating Margin Analysis
Neurogene's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Neurogene Operating Margin | (21.77) % |
Most of Neurogene's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurogene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neurogene Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurogene is extremely important. It helps to project a fair market value of Neurogene Stock properly, considering its historical fundamentals such as Operating Margin. Since Neurogene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurogene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurogene's interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Neurogene has an Operating Margin of -21.7665%. This is 37.95% lower than that of the Biotechnology sector and 80.58% lower than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Neurogene Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurogene's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurogene could also be used in its relative valuation, which is a method of valuing Neurogene by comparing valuation metrics of similar companies.Neurogene is currently under evaluation in operating margin category among its peers.
Neurogene ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neurogene's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neurogene's managers, analysts, and investors.Environmental | Governance | Social |
Neurogene Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (21.77) % | ||||
| Current Valuation | 211.85 M | ||||
| Shares Outstanding | 14.83 M | ||||
| Shares Owned By Insiders | 10.69 % | ||||
| Shares Owned By Institutions | 89.31 % | ||||
| Number Of Shares Shorted | 1.17 M | ||||
| Price To Book | 2.45 X | ||||
| Price To Sales | 363.58 X | ||||
| EBITDA | (52.29 M) | ||||
| Net Income | (36.32 M) | ||||
| Total Debt | 16.25 M | ||||
| Book Value Per Share | 11.93 X | ||||
| Cash Flow From Operations | (51.42 M) | ||||
| Short Ratio | 7.15 X | ||||
| Earnings Per Share | (3.66) X | ||||
| Target Price | 54.6 | ||||
| Number Of Employees | 91 | ||||
| Market Capitalization | 593.14 M | ||||
| Total Asset | 222.57 M | ||||
| Retained Earnings | (187.15 M) | ||||
| Working Capital | 177.38 M | ||||
| Net Asset | 222.57 M |
About Neurogene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out Neurogene Piotroski F Score and Neurogene Altman Z Score analysis. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.106 | Return On Assets (0.32) | Return On Equity (0.41) |
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.